The New England Journal of Medicine

Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction

Current guideline recommendations for the use of beta-blockers after myocardial infarction without reduced ejection fraction are based on trials conducted before routine reperfusion, invasive care, ...
Irish Medical Times

You might be interested in…Therapeutics Update (Part 1)

Dr Ray O’Connor looks at the latest clinical studies on therapeutics, including beta-lockers and potassium sparing diuretics ...
The New England Journal of Medicine

Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction

The therapeutic efficacy of the cardiac glycoside digitoxin in patients with heart failure and reduced ejection fraction is not established. In this international, double-blind, placebo-controlled ...
Nasdaq

Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction

SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF (Assessment of CK-586 in a Multi-Center, Blinded Evaluation of ...
Medscape

Pharmacologic Management of Heart Failure with Preserved Ejection Fraction

The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...